Skip to main content
Top
Published in: Tobacco Induced Diseases 1/2016

Open Access 01-12-2016 | Research

Experiences of COPD patients with existing smoking cessation programs and their preferences for improvement - a qualitative analysis

Authors: I. Aumann, L. Tedja, J. M. Graf von der Schulenburg

Published in: Tobacco Induced Diseases | Issue 1/2016

Login to get access

Abstract

Background

Smoking is a major risk factor for chronic obstructive pulmonary disease (COPD). For current smokers who are diagnosed with COPD, their first treatment option is to stop smoking. Motivation is necessary for long-term smoking cessation; therefore, when designing smoking cessation programs, the patients’ needs and preferences should be considered. We focused on COPD patients’ experiences with existing smoking cessation programs and evaluated their preferences for the improvement of these programs.

Methods

We conducted 18 guideline-based interviews with COPD patients between April and June 2014 in Germany. Each patient with COPD, who was a current or past smoker and had made at least one attempt to quit smoking in the past 5 years, was included in the study. We audiotaped, verbatim transcribed, and evaluated the interviews, using content analysis.

Results

The patients had broad and different experiences with pharmaceutical, behavioral, and alternative approaches that supported or negatively influenced the smoking cessation process. Pharmaceuticals were viewed as an expensive alternative with many side effects although they helped to stop cravings for a few moments. Furthermore, the bad structure and impersonal content of the seminars for smoking cessation negatively influenced group cohesion, and therefore degrading the patients’ motivation to stop smoking. Alternative methods, such as acupuncture and hypnosis were mostly ineffective in smoking cessation, but in some cases, served as motivational strategies.

Conclusion

Negative experiences with smoking cessation were explained by the patients’ lack of motivation or resolution. Other negative experiences, such as the structure of seminars for smoking cessation and the high price of pharmaceuticals should be addressed through policy changes to increase the patients’ motivation to quit smoking.
Literature
3.
go back to reference Lopez AD. Global burden of disease and risk factors. New York: Oxford University Press; World Bank; 2006.CrossRef Lopez AD. Global burden of disease and risk factors. New York: Oxford University Press; World Bank; 2006.CrossRef
4.
go back to reference Gibson GJ, Loddenkemper R, Lundback B, Sibille Y. Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J. 2013;42:559–63.CrossRefPubMed Gibson GJ, Loddenkemper R, Lundback B, Sibille Y. Respiratory health and disease in Europe: the new European Lung White Book. Eur Respir J. 2013;42:559–63.CrossRefPubMed
6.
go back to reference Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.CrossRefPubMedPubMedCentral Michie S, van Stralen MM, West R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Implement Sci. 2011;6:42.CrossRefPubMedPubMedCentral
7.
go back to reference Wilson JS, Elborn JS, Fitzsimons D. ‘It’s not worth stopping now’: why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. J Clin Nurs. 2011;20:819–27.CrossRefPubMed Wilson JS, Elborn JS, Fitzsimons D. ‘It’s not worth stopping now’: why do smokers with chronic obstructive pulmonary disease continue to smoke? A qualitative study. J Clin Nurs. 2011;20:819–27.CrossRefPubMed
8.
go back to reference Van Eerd EAM, Risør MB, van Rossem CR, van Schayck OCP, Kotz D. Experiences of tobacco smoking and quitting in smokers with and without chronic obstructive pulmonary disease-a qualitative analysis. BMC Fam Pract. 2015;16:164.CrossRefPubMedPubMedCentral Van Eerd EAM, Risør MB, van Rossem CR, van Schayck OCP, Kotz D. Experiences of tobacco smoking and quitting in smokers with and without chronic obstructive pulmonary disease-a qualitative analysis. BMC Fam Pract. 2015;16:164.CrossRefPubMedPubMedCentral
9.
10.
go back to reference van Eerd EAM, van Rossem C, Spigt MG, Wesseling G, van Schayck OCP, Kotz D. Do We Need Tailored Smoking Cessation Interventions for Smokers with COPD? A Comparative Study of Smokers with and without COPD Regarding Factors Associated with Tobacco. Respiration. 2015;90:211. van Eerd EAM, van Rossem C, Spigt MG, Wesseling G, van Schayck OCP, Kotz D. Do We Need Tailored Smoking Cessation Interventions for Smokers with COPD? A Comparative Study of Smokers with and without COPD Regarding Factors Associated with Tobacco. Respiration. 2015;90:211.
11.
go back to reference Flick U. An introduction to qualitative research. 4th ed. Los Angeles: Sage Publications; 2009. Flick U. An introduction to qualitative research. 4th ed. Los Angeles: Sage Publications; 2009.
13.
go back to reference Das Fünfte Buch Sozialgesetzbuch – Gesetzliche Krankenversicherung – (Artikel 1 des Gesetzes vom 20. Dezember 1988, BGBl. I S. 2477, 2482), das durch Artikel 1a des Gesetzes vom 31. Juli 2016 (BGBl. I S. 1937) geändert worden ist. Das Fünfte Buch Sozialgesetzbuch – Gesetzliche Krankenversicherung – (Artikel 1 des Gesetzes vom 20. Dezember 1988, BGBl. I S. 2477, 2482), das durch Artikel 1a des Gesetzes vom 31. Juli 2016 (BGBl. I S. 1937) geändert worden ist.
14.
go back to reference West R, DiMarino ME, Gitchell J, McNeill A. Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control. 2005;14:166–71.CrossRefPubMedPubMedCentral West R, DiMarino ME, Gitchell J, McNeill A. Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control. 2005;14:166–71.CrossRefPubMedPubMedCentral
15.
go back to reference World Health Organization. WHO report on the global tobacco epidemic, 2013: Enforcing bans on tobacco advertising, promotion and sponsorship. Geneva: World Health Organization; 2013. p. 2013. World Health Organization. WHO report on the global tobacco epidemic, 2013: Enforcing bans on tobacco advertising, promotion and sponsorship. Geneva: World Health Organization; 2013. p. 2013.
16.
go back to reference Eriksen MP, Mackay J, Schluger NW, Islami F, Drope J: The Tobacco Atlas, Fourth Edition. Atlanta, GA: American Cancer Society, and New York, NY: World Lung Foundation; 2012. Eriksen MP, Mackay J, Schluger NW, Islami F, Drope J: The Tobacco Atlas, Fourth Edition. Atlanta, GA: American Cancer Society, and New York, NY: World Lung Foundation; 2012.
17.
go back to reference van Boven JFM, Vemer P. Higher Adherence During Reimbursement of Pharmacological Smoking Cessation Treatments. Nicotine Tob Res. 2016;18:56–63.PubMed van Boven JFM, Vemer P. Higher Adherence During Reimbursement of Pharmacological Smoking Cessation Treatments. Nicotine Tob Res. 2016;18:56–63.PubMed
18.
go back to reference Cadier B, Durand-Zaleski I, Thomas D, Chevreul K, Gorlova OY. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases. PLoS ONE. 2016;11:e0148750.CrossRefPubMedPubMedCentral Cadier B, Durand-Zaleski I, Thomas D, Chevreul K, Gorlova OY. Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases. PLoS ONE. 2016;11:e0148750.CrossRefPubMedPubMedCentral
20.
go back to reference Houtsmuller EJ, Fant RV, Eissenberg TE, Henningfield JE, Stitzer ML. Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol Biochem Behav. 2002;72:559–68.CrossRefPubMed Houtsmuller EJ, Fant RV, Eissenberg TE, Henningfield JE, Stitzer ML. Flavor improvement does not increase abuse liability of nicotine chewing gum. Pharmacol Biochem Behav. 2002;72:559–68.CrossRefPubMed
21.
go back to reference Caldwell B, Burgess C, Crane J. Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Nicotine Tob Res. 2010;12:179–83.CrossRefPubMed Caldwell B, Burgess C, Crane J. Randomized crossover trial of the acceptability of snus, nicotine gum, and Zonnic therapy for smoking reduction in heavy smokers. Nicotine Tob Res. 2010;12:179–83.CrossRefPubMed
22.
go back to reference Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessation. In: Cochrane Database of Systematic Reviews. Chichester: Wiley; 1996. Stead LF, Perera R, Bullen C, Mant D, Hartmann-Boyce J, Cahill K, Lancaster T. Nicotine replacement therapy for smoking cessation. In: Cochrane Database of Systematic Reviews. Chichester: Wiley; 1996.
24.
go back to reference Tonnesen P, Carrozzi L, Fagerstrom KO, Gratziou C, Jimenez-Ruiz C, Nardini S, Viegi G, Lazzaro C, Campell IA, Dagli E, West R. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J. 2006;29:390–417.CrossRef Tonnesen P, Carrozzi L, Fagerstrom KO, Gratziou C, Jimenez-Ruiz C, Nardini S, Viegi G, Lazzaro C, Campell IA, Dagli E, West R. Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J. 2006;29:390–417.CrossRef
27.
go back to reference Bethea J, Murtagh B, Wallace SE. “I don’t mind damaging my own body” A qualitative study of the factors that motivate smokers to quit. BMC Public Health. 2015;15:4.CrossRefPubMedPubMedCentral Bethea J, Murtagh B, Wallace SE. “I don’t mind damaging my own body” A qualitative study of the factors that motivate smokers to quit. BMC Public Health. 2015;15:4.CrossRefPubMedPubMedCentral
28.
go back to reference Sundblad B, Larsson K, Nathell L. High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine Tob Res. 2008;10:883–90.CrossRefPubMed Sundblad B, Larsson K, Nathell L. High rate of smoking abstinence in COPD patients: Smoking cessation by hospitalization. Nicotine Tob Res. 2008;10:883–90.CrossRefPubMed
Metadata
Title
Experiences of COPD patients with existing smoking cessation programs and their preferences for improvement - a qualitative analysis
Authors
I. Aumann
L. Tedja
J. M. Graf von der Schulenburg
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Tobacco Induced Diseases / Issue 1/2016
Electronic ISSN: 1617-9625
DOI
https://doi.org/10.1186/s12971-016-0097-4

Other articles of this Issue 1/2016

Tobacco Induced Diseases 1/2016 Go to the issue